Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies

References

• American Medical Association . AMA adopts new policies on second day of voting at annual meeting. Chicago, IL: American Medical Association. 2013
   Google Scholar
• International Diabetes Federation . IDF diabetes atlas. 6th edition. Brussels, Belgium: International Diabetes Federation; 2013
   Google Scholar
• Age-Adjusted Percentage of Adults Aged 18 Years or Older with Diagnosed Diabetes Who Were Overweight, United States, 1994–2010. Centers for Disease Control and Prevention website 2014. Available from www.cdc.gov/diabetes/statistics/comp/fig7_overweight.htm. Accessed February 13, 2015
   Google Scholar
• Pi-Sunyer FX . Weight loss in type 2 diabetic patients. Diabetes Care 2005;28:1526–7
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group . Lancet 1998;352:837–53
   PubMed Web of Science ®Google Scholar
• Inzucchi SE , Bergenstal RM , Buse JB , Diamant M , Ferrannini E , Nauck M , et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–79
   PubMed Web of Science ®Google Scholar
• Wing RR , Lang W , Wadden TA , Safford M , Knowler WC , Bertoni AG , et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481–6
   PubMed Web of Science ®Google Scholar
• Yamagishi SI , Nakamura K , Matsui T , Ueda SI , Imaizumi T . Role of postprandial hyperglycaemia in cardiovascular disease in diabetes. Int J Clin Pract 2007;61:83–7
   PubMed Web of Science ®Google Scholar
• Kim YI , Kim CH , Choi CS , Chung YE , Lee MS , Lee S , et al. Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population. Diabetes Res Clin Pract 2001;52:145–52
   PubMed Web of Science ®Google Scholar
• Franklin GM , Kahn LB , Baxter J , Marshall JA , Hamman RF . Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990;131:633–43
   PubMed Web of Science ®Google Scholar
• Ziegler D , Rathmann W , Dickhaus T , Meisinger C , Mielck A . Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008;31:464–9
   PubMed Web of Science ®Google Scholar
• Khaw KT , Wareham N , Bingham S , Luben R , Welch A , Day N . Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413–20
   PubMed Web of Science ®Google Scholar
• Stratton IM , Adler AI , Neil HA , Matthews DR , Manley SE , Cull CA , et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12
   PubMed Web of Science ®Google Scholar
• Skyler JS , Bergenstal R , Bonow RO , Buse J , Deedwania P , Gale EA , et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187–92
   PubMed Web of Science ®Google Scholar
• Nathan DM , Cleary PA , Backlund JY , Genuth SM , Lachin JM , Orchard TJ , et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–53
   PubMed Web of Science ®Google Scholar
• Holman RR , Paul SK , Bethel MA , Matthews DR , Neil HA . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89
   PubMed Web of Science ®Google Scholar
• Mitri J , Hamdy O . Diabetes medications and body weight. Expert Opin Drug Saf 2009;8:573–84
   PubMed Web of Science ®Google Scholar
• Khunti K , Davies M , Majeed A , Thorsted BL , Wolden ML , Paul SK . Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 2015;38:316–22
   PubMed Web of Science ®Google Scholar
• Groop LC . Sulfonylureas in NIDDM. Diabetes Care 1992;15:737–54
   PubMed Web of Science ®Google Scholar
• Nathan DM , Buse JB , Davidson MB , Ferrannini E , Holman RR , Sherwin R , et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193–203
   PubMed Web of Science ®Google Scholar
• Hirst JA , Farmer AJ , Dyar A , Lung TW , Stevens RJ . Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013;56:973–84
   PubMed Web of Science ®Google Scholar
• Phung OJ , Schwartzman E , Allen RW , Engel SS , Rajpathak SN . Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med 2013;30:1160–71
   PubMed Web of Science ®Google Scholar
• Maedler K , Carr RD , Bosco D , Zuellig RA , Berney T , Donath MY . Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501–6
   PubMed Web of Science ®Google Scholar
• Takahashi A , Nagashima K , Hamasaki A , Kuwamura N , Kawasaki Y , Ikeda H , et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract 2007;77:343–50
   PubMed Web of Science ®Google Scholar
• Phung OJ , Scholle JM , Talwar M , Coleman CI . Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410–18
   PubMed Web of Science ®Google Scholar
• DeFronzo RA . Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–95
   PubMed Web of Science ®Google Scholar
• Kahn SE , Haffner SM , Heise MA , Herman WH , Holman RR , Jones NP , et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–43
   PubMed Web of Science ®Google Scholar
• Turner RC , Cull CA , Frighi V , Holman RR . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• Garber AJ , Abrahamson MJ , Barzilay JI , Blonde L , Bloomgarden ZT , Bush MA , et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327–36
   PubMed Web of Science ®Google Scholar
• Garber AJ , Abrahamson MJ , Barzilay JI , Blonde L , Bloomgarden ZT , Bush MA , et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013;19:1–48
   PubMed Web of Science ®Google Scholar
• Patel A , MacMahon S , Chalmers J , Neal B , Billot L , Woodward M , et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72
   PubMed Web of Science ®Google Scholar
• Nichols GA , Gomez-Caminero A . Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007;9:96–102
   PubMed Web of Science ®Google Scholar
• Hemmingsen B , Schroll JB , Wetterslev J , Gluud C , Vaag A , Sonne DP , et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2014;2:E162–75
   PubMedGoogle Scholar
• Chico A , Vidal-Ríos P , Subirà M , Novials A . The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003;26:1153–7
   PubMed Web of Science ®Google Scholar
• Weber KK , Lohmann T , Busch K , Donati-Hirsch I , Riel R . High frequency of unrecognized hypoglycaemias in patients with Type 2 diabetes is discovered by continuous glucose monitoring. Exp Clin Endocrinol Diabetes 2007;115:491–4
   PubMed Web of Science ®Google Scholar
• Zick R , Petersen B , Richter M , Haug C . Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther 2007;9:483–92
   PubMed Web of Science ®Google Scholar
• Holstein A , Plaschke A , Egberts EH . Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467–73
   PubMed Web of Science ®Google Scholar
• Gangji AS , Cukierman T , Gerstein HC , Goldsmith CH , Clase CM . A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389–94
   PubMed Web of Science ®Google Scholar
• Malaisse WJ . Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003;2:401–14
   PubMedGoogle Scholar
• Winkler M , Stephan D , Bieger S , Kuhner P , Wolff F , Quast U . Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands. J Pharmacol Exp Ther 2007;322:701–8
   PubMed Web of Science ®Google Scholar
• Melander A . Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Diabetes 2004;53:S151–5
   PubMed Web of Science ®Google Scholar
• Dornhorst A . Insulinotropic meglitinide analogues. Lancet 2001;358:1709–16
   PubMed Web of Science ®Google Scholar
• Rosenstock J , Hassman DR , Madder RD , Brazinsky SA , Farrell J , Khutoryansky N , et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27:1265–70
   PubMed Web of Science ®Google Scholar
• Raskin P , Klaff L , McGill J , South SA , Hollander P , Khutoryansky N , et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003;26:2063–8
   PubMed Web of Science ®Google Scholar
• Gerich J , Raskin P , Jean-Louis L , Purkayastha D , Baron MA . PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005;28:2093–9
   PubMed Web of Science ®Google Scholar
• Khoo J , Rayner CK , Jones KL , Horowitz M . Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag 2009;5:683–98
   PubMedGoogle Scholar
• Amori RE , Lau J , Pittas AG . Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194–206
   PubMed Web of Science ®Google Scholar
• TANZEUM (albiglutide) Prescribing Information. Wilmington, DE: GlaxoSmithKline LLC; 2014
   Google Scholar
• TRULICITY (dulaglutide) Prescribing Information. Indianapolis, IN: Eli Lilly and Company; 2014
   Google Scholar
• Cernea S , Raz I . Therapy in the early stage: incretins. Diabetes Care 2011;34:S264–71
   PubMed Web of Science ®Google Scholar
• Astrup A , Rossner S , Van Gaal L , Rissanen A , Niskanen L , Al Hakim M , et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606–16
   PubMed Web of Science ®Google Scholar
• Buse JB , Rosenstock J , Sesti G , Schmidt WE , Montanya E , Brett JH , et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47
   PubMed Web of Science ®Google Scholar
• Buse JB , Drucker DJ , Taylor KL , Kim T , Walsh B , Hu H , et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255–61
   PubMed Web of Science ®Google Scholar
• Russell-Jones D , Cuddihy RM , Hanefeld M , Kumar A , González JG , Chan M , et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252–8
   PubMed Web of Science ®Google Scholar
• Moretto TJ , Milton DR , Ridge TD , Macconell LA , Okerson T , Wolka AM , et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448–60
   PubMed Web of Science ®Google Scholar
• Shomali M . Optimizing the care of patients with type 2 diabetes using incretin-based therapy: Focus on GLP-1 receptor agonists. Clin Diabetes 2014;32:32–43
   PubMedGoogle Scholar
• Drucker DJ . Incretin-based therapy and the quest for sustained improvements in beta-cell health. Diabetes Care 2011;34:2133–5
   PubMed Web of Science ®Google Scholar
• Best JH , Hoogwerf BJ , Herman WH , Pelletier EM , Smith DB , Wenten M , et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011;34:90–5
   PubMed Web of Science ®Google Scholar
• Knop FK , Holst JJ , Vilsboll T . Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. IDrugs 2008;11:497–501
   PubMed Web of Science ®Google Scholar
• Bailey CJ , Turner RC . Metformin. N Engl J Med 1996;334:574–9
   PubMed Web of Science ®Google Scholar
• DeFronzo RA , Goodman AM . Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541–9
   PubMed Web of Science ®Google Scholar
• Inzucchi SE , Bergenstal RM , Buse JB , Diamant M , Ferrannini E , Nauck M , et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–9
   PubMed Web of Science ®Google Scholar
• Salpeter SR , Greyber E , Pasternak GA , Salpeter EE . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010:CD002967
   Web of Science ®Google Scholar
• Inzucchi SE , Lipska KJ , Mayo H , Bailey CJ , McGuire DK . Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014;312:2668–75
   PubMed Web of Science ®Google Scholar
• Knowler WC , Barrett-Connor E , Fowler SE , Hamman RF , Lachin JM , Walker EA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group . Lancet 1998;352:854–65
   PubMed Web of Science ®Google Scholar
• Knowler WC , Fowler SE , Hamman RF , Christophi CA , Hoffman HJ , Brenneman AT , et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677–86
   PubMed Web of Science ®Google Scholar
• Charbonnel B , Roden M , Urquhart R , Mariz S , Johns D , Mihm M , et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia 2005;48:553–60
   PubMed Web of Science ®Google Scholar
• Dormandy JA , Charbonnel B , Eckland DJ , Erdmann E , Massi-Benedetti M , Moules IK , et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–89
   PubMed Web of Science ®Google Scholar
• Lincoff AM , Wolski K , Nicholls SJ , Nissen SE . Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180–8
   PubMed Web of Science ®Google Scholar
• ACTOS (pioglitazone) tablets for oral use Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2013
   Google Scholar
• Lecka-Czernik B . Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 2010;8:178–84
   PubMedGoogle Scholar
• Aithal GP , Thomas JA , Kaye PV , Lawson A , Ryder SD , Spendlove I , et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176–84
   PubMed Web of Science ®Google Scholar
• Gastaldelli A , Harrison S , Belfort-Aguiar R , Hardies J , Balas B , Schenker S , et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 2010;32:769–75
   PubMed Web of Science ®Google Scholar
• Kushner RF , Sujak M . Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone. Obesity (Silver Spring) 2009;17:1017–22
   PubMed Web of Science ®Google Scholar
• Gupta AK , Smith SR , Greenway FL , Bray GA . Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab 2009;11:330–7
   PubMed Web of Science ®Google Scholar
• Schwartz S . Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide. Curr Med Res Opin 2008;24:3009–22
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes--2015. Diabetes Care 2015;38:S1–S94
   PubMed Web of Science ®Google Scholar
• Vivian EM . Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context 2014;3:212264
   PubMedGoogle Scholar
• Wilding JP . The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism 2014;63:1228–37
   PubMed Web of Science ®Google Scholar
• Foote C , Perkovic V , Neal B . Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012;9:117–23
   PubMed Web of Science ®Google Scholar
• Wysham CH , Woo VC , Mathieu C , Desai M , Alba M , Capubano G , et al. Canagliflozin (CANA) Added on to Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) or Glucagon-Like Peptide-1 (GLP-1) Agonists With or Without Other Antihyperglycemic Agents (AHAs) in Type 2 Diabetes Mellitus (T2DM). American Diabetes Association 73rd Scientific Sessions, 1080-P. 2013
   Google Scholar
• Schwartz S . Evidence-based practice use of incretin-based therapy in the natural history of diabetes. Postgrad Med 2014;126:66–84
   PubMed Web of Science ®Google Scholar
• Calado J , Sznajer Y , Metzger D , Rita A , Hogan MC , Kattamis A , et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant 2008;23:3874–9
   PubMed Web of Science ®Google Scholar
• Chao EC . Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. Core Evid 2012;7:21–8
   PubMedGoogle Scholar
• Rodbard HW , Jellinger PS , Davidson JA , Einhorn D , Garber AJ , Grunberger G , et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540–59
   PubMed Web of Science ®Google Scholar
• Schwartz SS . A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Curr Med Res Opin 2013;29:793–9
   PubMed Web of Science ®Google Scholar
• Schwartz S , Fabricatore AN , Diamond A . Weight reduction in diabetes. In: Ahmad SI, editor. Diabetes: An old disease, a new insight. New York: Springer Science+Business Media LLC; 2012. 438–58
   Google Scholar
• Yancy WS Jr , Foy M , Chalecki AM , Vernon MC , Westman EC . A low-carbohydrate, ketogenic diet to treat type 2 diabetes. Nutr Metab (Lond) 2005;2:34
   PubMedGoogle Scholar
• Garber AJ , King AB , Del Prato S , Sreenan S , Balci MK , Muñoz-Torres M , et al. Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498–507
   PubMed Web of Science ®Google Scholar
• Zieve FJ , Kalin MF , Schwartz SL , Jones MR , Bailey WL . Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74–83
   PubMed Web of Science ®Google Scholar
• Sonnett TE , Levien TL , Neumiller JJ , Gates BJ , Setter SM . Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. Clin Ther 2009;31:245–59
   PubMed Web of Science ®Google Scholar
• Holt RI , Barnett AH , Bailey CJ . Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab 2010;12:1048–57
   PubMed Web of Science ®Google Scholar
• Gaziano JM , Cincotta AH , O’Connor CM , Ezrokhi M , Rutty D , Ma ZJ , et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33:1503–8
   PubMed Web of Science ®Google Scholar
• Scranton R , Cincotta A . Bromocriptine -- unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother 2010;11:269–79
   PubMed Web of Science ®Google Scholar
• Ezrokhi M , Luo S , Trubitsyna Y , Cincotta AH . Synergism of dopamine agonist plus GLP-1 analog therapy on improvement of glucose intolerance in Syrian hamsters. 71st Scientific Sessions of the American Diabetes Association, 1633-P 2011
   Google Scholar
• Van de Laar FA , Lucassen PL , Akkermans RP , Van de Lisdonk EH , Rutten GE , Van Weel C . Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005:CD003639
   PubMed Web of Science ®Google Scholar
• Chiasson JL , Josse RG , Gomis R , Hanefeld M , Karasik A , Laakso M . Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072–7
   PubMed Web of Science ®Google Scholar
• Chiasson JL , Josse RG , Gomis R , Hanefeld M , Karasik A , Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–94
   PubMed Web of Science ®Google Scholar
• Riddle M , Frias J , Zhang B , Maier H , Brown C , Lutz K , et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007;30:2794–9
   PubMed Web of Science ®Google Scholar
• SYMLIN (pramlintide acetate) injection for subcutaneous use Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014
   Google Scholar
• Chisholm JW , Goldfine AB , Dhalla AK , Braunwald E , Morrow DA , Karwatowska-Prokopczuk E , et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 2010;33:1163–8
   PubMed Web of Science ®Google Scholar
• Morrow DA , Scirica BM , Chaitman BR , McGuire DK , Murphy SA , Karwatowska-Prokopczuk E , et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119:2032–9
   PubMed Web of Science ®Google Scholar
• Schwartz S . Diet. 2015. Available from http://schwartzdiabetesdoc.com/. Accessed February 1, 2015
   Google Scholar
• Sniderman AD , LaChapelle KJ , Rachon NA , Furberg CD . The necessity for clinical reasoning in the era of evidence-based medicine. Mayo Clin Proc 2013;88:1108–14
   PubMed Web of Science ®Google Scholar
• Greenhalgh T , Howick J , Maskrey N . Evidence based medicine: a movement in crisis? BMJ 2014;348:g3725
   PubMed Web of Science ®Google Scholar
• Rosenstock J , Aggarwal N , Polidori D , Zhao Y , Arbit D , Usiskin K , et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232–8
   PubMed Web of Science ®Google Scholar
• Wadden TA , Hollander P , Klein S , Niswender K , Woo V , Hale PM , et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013;37:1443–51
   PubMed Web of Science ®Google Scholar
• Bell DS . The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss. Am J Case Rep 2014;15:152–4
   PubMedGoogle Scholar
• Mcgovern AP , Dutta N , Watters K , Munro N , Feher M . Additive weight loss effect with a combination of an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) agonist in Type 2 diabetes. Diabetes UK Professional Conference, P143. 2015
   Google Scholar
• Zinman B , Hoogwerf BJ , Durán Garcia S , Milton DR , Giaconia JM , Kim DD , et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477–85
   PubMed Web of Science ®Google Scholar
• Buse JB , Peters A , Russell-Jones D , Furber S , Donsmark M , Han J , et al. Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes Obes Metab 2015;17:145–51
   PubMed Web of Science ®Google Scholar
• Standards of medical care in diabetes. Diabetes Care 2005;28:S4–36
   PubMed Web of Science ®Google Scholar
• Banerji MA , Chaiken RL , Huey H , Tuomi T , Norin AJ , Mackay IR , et al. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. Flatbush diabetes. Diabetes 1994;43:741–5
   PubMed Web of Science ®Google Scholar
• Jensen MD , Ryan DH , Apovian CM , Ard JD , Comuzzie AG , Donato KA , et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014;129:S102–38
   PubMed Web of Science ®Google Scholar
• Shai I , Schwarzfuchs D , Henkin Y , Shahar DR , Witkow S , Greenberg I , et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008;359:229–41
   PubMed Web of Science ®Google Scholar
• Johnston BC , Kanters S , Bandayrel K , Wu P , Naji F , Siemieniuk RA , et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 2014;312:923–33
   PubMed Web of Science ®Google Scholar
• Rosenbaum M , Leibel RL , Hirsch J . Obesity. N Engl J Med 1997;337:396–407
   PubMed Web of Science ®Google Scholar
• Hall KD , Sacks G , Chandramohan D , Chow CC , Wang YC , Gortmaker SL , Swinburn BA . Quantification of the effect of energy imbalance on bodyweight. Lancet 2011;378:826–37
   PubMed Web of Science ®Google Scholar
• Slentz CA , Duscha BD , Johnson JL , Ketchum K , Aiken LB , Samsa GP , et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE--a randomized controlled study. Arch Intern Med 2004;164:31–9
   PubMed Web of Science ®Google Scholar
• Foster GD , Makris AP , Bailer BA . Behavioral treatment of obesity. Am J Clin Nutr 2005;82:230S–5S
   PubMed Web of Science ®Google Scholar
• Guidelines on Overweight and Obesity: Electronic Textbook. NHLBI website 2015. Available from http://www.nhlbi.nih.gov/health-pro/guidelines/current/obesity-guidelines/e_textbook/txgd/4323.htm. Accessed February 12, 2015
   Google Scholar
• Ochner CN , Tsai AG , Kushner RF , Wadden TA . Treating obesity seriously: when recommendations for lifestyle change confront biological adaptations. Lancet Diabetes Endocrinol 2015;3:232–4
   PubMed Web of Science ®Google Scholar
• Yanovski SZ , Yanovski JA . Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74–86
   PubMed Web of Science ®Google Scholar
• Apovian CM , Aronne LJ , Bessesen DH , McDonnell ME , Murad MH , Pagotto U , et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342–62
   PubMed Web of Science ®Google Scholar
• XENICAL (orlistat) capsules for oral use Prescribing Information. South San Francisco, CA: Genentech USA, Inc; 2013
   Google Scholar
• Torgerson JS , Hauptman J , Boldrin MN , Sjostrom L . XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–61
   PubMed Web of Science ®Google Scholar
• BELVIQ (lorcaserin hydrochloride) US Prescribing Information. Woodcliff Lake, NJ: Eisai Inc; 2014
   Google Scholar
• Heisler LK , Jobst EE , Sutton GM , Zhou L , Borok E , Thornton-Jones Z , et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006;51:239–49
   PubMed Web of Science ®Google Scholar
• O’Neil PM , Smith SR , Weissman NJ , Fidler MC , Sanchez M , Zhang J , et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426–36
   PubMed Web of Science ®Google Scholar
• Fabbrini E , Fain R , Glicklich A , Li Y , Shanahan W , Soliman W . Early Effects of Lorcaserin (LOR) on Glycemic Parameters in Obese and Overweight Patients (pts) with Type 2 Diabetes Mellitus (T2D): A Retrospective Analysis of BLOOM-DM. Obesity Week, T-3028-OR. 2014
   Google Scholar
• Smith SR , Weissman NJ , Anderson CM , Sanchez M , Chuang E , Stubbe S , et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245–56
   PubMed Web of Science ®Google Scholar
• FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen) (press release). 1997. Available from www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm. Accessed March 10, 2015
   Google Scholar
• Thomsen WJ , Grottick AJ , Menzaghi F , Reyes-Saldana H , Espitia S , Yuskin D , et al. Lorcaserin, a novel selective human 5-hydroxytryptamine(2C) agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325:577–87
   PubMed Web of Science ®Google Scholar
• Weissman NJ , Sanchez M , Koch GG , Smith SR , Shanahan WR , Anderson CM . Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 2013;6:560–7
   PubMed Web of Science ®Google Scholar
• QSYMIA (phentermine and topiramate extended-release) capsules Prescribing Information. Mountain View, CA: VIVUS, Inc; 2014
   Google Scholar
• Kushner RF , Apovian CM , Fujioka K . Obesity consults -- comprehensive obesity management in 2013: understanding the shifting paradigm. Obesity (Silver Spring) 2013;21:S3–13
   PubMed Web of Science ®Google Scholar
• Allison DB , Gadde KM , Garvey WT , Peterson CA , Schwiers ML , Najarian T , et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330–42
   PubMed Web of Science ®Google Scholar
• Gadde KM , Allison DB , Ryan DH , Peterson CA , Troupin B , Schwiers ML , Day WW . Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341–52
   PubMed Web of Science ®Google Scholar
• Garvey WT , Ryan DH , Look M , Gadde KM , Allison DB , Peterson CA , et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297–308
   PubMed Web of Science ®Google Scholar
• Smith SM , Meyer M , Trinkley KE . Phentermine/topiramate for the treatment of obesity. Ann Pharmacother 2013;47:340–9
   PubMed Web of Science ®Google Scholar
• Greenway FL , Fujioka K , Plodkowski RA , Mudaliar S , Guttadauria M , Erickson J , et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595–605
   PubMed Web of Science ®Google Scholar
• Hollander P , Gupta AK , Plodkowski R , Greenway F , Bays H , Burns C , et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36:4022–9
   PubMed Web of Science ®Google Scholar
• CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2014
   Google Scholar
• Apovian CM , Aronne L , Rubino D , Still C , Wyatt H , Burns C , et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21:935–43
   PubMed Web of Science ®Google Scholar
• SAXENDA (liraglutide [rDNA origin] injection) Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc; 2014
   Google Scholar
• FDA Approves Weight-Management Drug Saxenda (press release). 2014. Available from www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm. Accessed March 10, 2015
   Google Scholar
• VICTOZA (liraglitude injection) Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc; 2013
   Google Scholar
• van Bloemendaal L , Ten Kulve JS , la Fleur SE , Ijzerman RG , Diamant M . Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014;221:T1–16
   PubMed Web of Science ®Google Scholar
• Hellstrom PM . Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility. Vitam Horm 2010;84:319–29
   PubMed Web of Science ®Google Scholar
• Lockie SH , Heppner KM , Chaudhary N , Chabenne JR , Morgan DA , Veyrat-Durebex C , et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 2012;61:2753–62
   PubMed Web of Science ®Google Scholar
• Egan AG , Blind E , Dunder K , de Graeff PA , Hummer BT , Bourcier T , Rosebraugh C . Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med 2014;370:794–7
   PubMed Web of Science ®Google Scholar
• Thomsen RW , Pedersen L , Moller N , Kahlert J , Beck-Nielsen H , Sorensen HT . Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Faillie JL , Azoulay L , Patenaude V , Hillaire-Buys D , Suissa S . Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ 2014;348:g2780
   PubMed Web of Science ®Google Scholar
• DeMaria EJ , Pate V , Warthen M , Winegar DA . Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis 2010;6:347–55
   PubMed Web of Science ®Google Scholar
• Buchwald H , Estok R , Fahrbach K , Banel D , Jensen MD , Pories WJ , et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248–56
   PubMed Web of Science ®Google Scholar
• Mechanick JI , Youdim A , Jones DB , Garvey WT , Hurley DL , McMahon M , et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring) 2013;21:S1–27
   PubMed Web of Science ®Google Scholar
• Dogan K , Betzel B , Homan J , Aarts EO , Ploeger N , de Boer H , et al. Long-term effects of laparoscopic Roux-en-Y gastric bypass on diabetes mellitus, hypertension and dyslipidaemia in morbidly obese patients. Obes Surg 2014;24:1835–42
   PubMed Web of Science ®Google Scholar
• Colquitt JL , Pickett K , Loveman E , Frampton GK . Surgery for weight loss in adults. Cochrane Database Syst Rev 2014;8:CD003641
   PubMed Web of Science ®Google Scholar
• Koehestanie P , de Jong C , Berends FJ , Janssen IM , Bouvy ND , Greve JW . The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg 2014;260:984–92
   PubMed Web of Science ®Google Scholar
• Armato J , DeFronzo RA , Abdul-Ghani M , Ruby R . Successful treatment of prediabetes in clinical practice: targeting insulin resistance and beta-cell dysfunction. Endocr Pract 2012;18:342–50
   PubMed Web of Science ®Google Scholar
• STARLIX (nateglinide) Tablets Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013
   Google Scholar
• PRANDIN (repaglinide) Tablets Prescribing Information. Princeton, NJ: Novo Nordisk Inc; 2008
   Google Scholar
• BYETTA (exenatide) Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014
   Google Scholar
• TRADJENTA (linagliptin) Tablets Prescribing Information. Ingelheim, Germany: Boehringer Ingelheim International GmbH; 2014
   Google Scholar
• ONGLYZA (saxagliptin) Tablets Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014
   Google Scholar
• JANUVIA (sitagliptin) Tablets Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc; 2014
   Google Scholar
• NESINA (alogliptin) Tablets Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2013
   Google Scholar
• GALVUS (vildagliptin) Prescribing Information. North Ryde, Australia: Novartis Pharmaceuticals; 2014
   Google Scholar
• GLUCOPHAGE XR (metformin hydrochloride) Extended Release Tablets Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2009
   Google Scholar
• PRECOSE (acarbose) Tablets Prescribing Information. Germany: Bayer HealthCare Pharmaceuticals Inc; 2011
   Google Scholar
• GLYSET (miglitol) Tablets Prescribing Information. Germany: Bayer HealthCare Pharmaceuticals, Inc; 2012
   Google Scholar
• WELCHOL (colesevelam hydrochloride) Prescribing Information. Parsippany, NJ: Daiichi Sankyo Inc; 2014
   Google Scholar
• CYCLOSET (bromocriptine mesylate) Tablets Prescribing Information. Tiverton, RI: VeroScience LLC; 2009
   Google Scholar
• GLUCOTROL XL (glipizide) Extended Release Tablets Prescribing Information. New York, NY: Roerig, Division of Pfizer, Inc; 2006
   Google Scholar
• DiaBeta (glyburide) Tablets Prescribing Information. Bridgewater, NJ: Sanofi-Aventis; 2009
   Google Scholar
• AMARYL (glimepiride) Tablets Prescribing Information. Bridgewater, NJ: Sanofi-Aventis; 2009
   Google Scholar
• Riddle MC , Rosenstock J , Gerich J . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080–6
   PubMed Web of Science ®Google Scholar
• Hermansen K , Davies M , Derezinski T , Martinez Ravn G , Clauson P , Home P. A . 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269–74
   PubMed Web of Science ®Google Scholar
• RANEXA (ranolazine) Prescribing Information. Foster City, CA: Gilead Sciences, Inc; 2013
   Google Scholar
• Maglione MA , Maggard Gibbons M , Livhits M , Ewing B , Hu J , Ruelaz Maher A , et al. Bariatric Surgery and Nonsurgical Therapy in Adults With Metabolic Conditions and a Body Mass Index of 30.0 to 34.9 kg/m². Comparative Effectiveness Review No. 82. Rockville, MD: Agency for Healthcare Research and Quality; 2013; AHRQ Publication No. 12(13)-EHC139-EF
   Google Scholar